or
forgot password

Phase I Alimta Combination With BMS-275183 (Oral Taxane)


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Non-small Cell Lung Cancer

Thank you

Trial Information

Phase I Alimta Combination With BMS-275183 (Oral Taxane)


Inclusion Criteria:



- Advanced or metastatic pretreated NSCLC

- Measurable disease

- Adequate hematologic, hepatic and renal functions.

- ECOG Performance Status 0-2

Exclusion Criteria:

- Inability to swallow capsules

- Recent significant cardiovascular disease

- Women who are pregnant or breastfeeding

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

CA165-021

NCT ID:

NCT00103831

Start Date:

Completion Date:

Related Keywords:

  • Non-Small Cell Lung Cancer
  • NSCLC - non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
Local Institution Aurora, Colorado  
Local Institution Duluth, Minnesota